Silexion Therapeutics Corp. has announced amendments to its bylaws following shareholder approval of a 1-for-15 reverse share split. Effective July 28, 2025, the company's ordinary shares will trade on a split-adjusted basis on Nasdaq. The reverse split, approved at the 2025 Annual General Meeting, decreases issued and outstanding shares while maintaining the authorized share capital at $20,000, adjusting the par value of shares from $0.0009 to $0.0135. The trading symbol "SLXN" remains unchanged.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002515), on July 29, 2025, and is solely responsible for the information contained therein.